Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed antibody conjugated with the topoisomerase I inhibitory drug, SN-38, via a proprietary hydrolysable linker ...

the most common form of bladder cancer. The results of the TROPiCS-04 study compared Trodelvy (sacituzumab govitecan) to chemotherapy as second-line treatment for patients with locally advanced or ...

There are two antibody-drug conjugates approved for the treatment of bladder cancer: sacituzumab govitecan (Trodelvy), which targets the Trop-2 protein on cancer cells, and enfortumab vedotin ...

Read more about A trial of sacituzumab govitecan for urothelial cancer (urinary tract cancer ... A study of durvalumab and the vaccine S-488210/S-488211 for bladder cancer (DURANCE) This study is ...

In the study, Trodelvy (sacituzumab govitecan) met its objective of ... approved indication of triple-negative breast cancer (TNBC) and bladder cancer, and justify the $21 billion the company ...

FDA granted Fast Track designation to XMT-1660 for advanced HER2-low/negative breast cancer, including TNBC ... In the ASCENT Phase 3 trial of sacituzumab govitecan, the ORR with standard-of ...

Last month, the Dutch Ministry of Health, Welfare and Sport (VWS) announced that it will not include the cancer drug Trodelvy (sacituzumab govitecan-hziy) in the country’s standard package of ...